Monopar Therapeutics Inc.
MNPR
$60.63
$0.020.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 9.57% | 11.99% | -200.27% | -142.96% | -117.78% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -44.47% | -29.60% | 531.26% | 367.67% | 276.56% |
| Change in Net Operating Assets | 403.47% | -171.07% | 121.63% | 96.91% | 68.73% |
| Cash from Operations | 3.84% | -90.52% | -81.96% | -43.92% | -43.76% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -402.24% | -342.54% | -625.28% | -733.56% | -377.63% |
| Cash from Investing | -402.24% | -342.54% | -625.28% | -733.56% | -377.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 127.28% | 115.15% | 5,108.54% | 1,384.46% | 1,164.72% |
| Repurchase of Common Stock | -16,063.92% | -34,692.41% | -84,373.18% | -1,467.54% | -450.25% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 63.39% | 54.45% | 4,143.44% | 1,383.74% | 1,171.36% |
| Foreign Exchange rate Adjustments | 3,028.57% | 19,340.00% | -48.78% | -11.11% | 127.27% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -59.78% | -58.45% | 24,000.08% | 3,149.14% | 1,432.37% |